Yoon Yoon personal page - To The Moon

Yoon Yoon

Yoon Yoon

No personal profile

27Follow

0Followers

1Topic

0Badge

05-15

Great article, would you like to share it?

@Tiger_Academy:第二課：投資美國國債嘅優勢和風險

05-15

Cheers to a great start!

Find out more here: Cheers to a great start! Receive rewards up to USD 3600*

Cheers to a great start!

05-14

Share your opinion about this news…

Sorry, the original content has been removed

05-11

Great article, would you like to share it?

SG Morning Call | STI Rose 0.02%, SIA Rose 1%, Singtel Rose 0.8%, SATS LTD Rose 0.8%

05-11

$CHINA TELECOM(00728)$

05-11

$CHINA TELECOM(00728)$

05-11

$Tiger Brokers(TIGR)$ $BioNTech SE(BNTX)$

05-11

$Tiger Brokers(TIGR)$

05-11

Share your opinion about this news…

Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability

05-11

Great article, would you like to share it?

Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability

05-11

Cheers to a great start!

Find out more here: Cheers to a great start! Receive rewards up to USD 3600*

Cheers to a great start!

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":4178343809649462,"uuid":"4178343809649462","gmtCreate":1715242747794,"gmtModify":1715379012265,"name":"Yoon Yoon","pinyin":"yoonyoonyoonyoon","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":27,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":306188966731800,"gmtCreate":1715788413641,"gmtModify":1715788415788,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/306188966731800","repostId":"296191808987136","repostType":1,"repost":{"id":296191808987136,"gmtCreate":1713323138862,"gmtModify":1713334657534,"author":{"id":"4104455119105420","authorId":"4104455119105420","name":"Tiger_Academy","avatar":"https://static.tigerbbs.com/3776fe550cd7a945e43d68c025988ed8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"第二課：投資美國國債嘅優勢和風險","htmlText":"虎友，你好！喺上節課中，我哋主要探討了債券嘅定義和分類，並瞭解了債券嘅五個基本要素。呢節課，我將帶你學習：點解要投資美國國債以及投資風險。此外，我還會手把手教你點樣計算美國國債嘅回報。一、點解要投資美國國債許多虎友可能會講，與股票、期權等資產相比，美國國債嘅回報太低，感覺冇乜吸引力。梗系，如果只睇未嚟嘅潛喺回報率，債券似乎確實唔咁吸引人。但從長期資產配置和風險管理嘅角度嚟睇，美國國債具有三個獨特嘅優點：1、投資門檻低唔同於許多其他需要高起點投資嘅債券產品，喺 老虎證券app 上，購買債券嘅門檻非常低。以美國國債為例，目前喺老虎證券app上，最低只需1000美元就可以投資國債。此外，購買國債嘅交易過程非常簡單，類似於購買股票，我將喺最後一課詳細介紹交易步驟。2、風險較低相對於股票、期權等資產，債券嘅風險較低。如果你購買嘅系像美國國債呢種具有主權背書嘅債券，基本上唔會面臨信用風險。畢竟，迄今為止，美國國債從未發生過信用違約。3、收益穩健債券提供固定嘅票息，只要持有，就可以按期獲得派息，唔受市場波動嘅影響，回報相對穩定。喺到期後，你還能拿回你嘅投資本金，呢非常適合啲唔願承擔高風險嘅投資者。二、債券投資嘅兩大風險盡管美國國債具有低門檻、低風險和穩定回報嘅特點，但仍然存在一些潛喺風險。除咗匯率因素外，投資債券主要會面臨兩種風險：信用風險和利率風險。1、信用風險信用風險係指債券發行者無法按時償還本金或支付利息嘅風險。信用風險對債券嘅影響非常重要，因為佢直接影響着債券嘅價格和投資回報。一般嚟講，信用質量較高嘅債券通常具有較低嘅回報率，而信用質量較低嘅債券通常具有較高嘅回報率。像養老金基金和保險公司呢類機構投資者，通常更傾向於持有高信用債券，因為佢哋更加關注本金和穩定嘅利息支付。另一些機構投資者，如高收益債券基金，可能更傾向於尋求較高回報，肯承擔較高嘅信用風險。2、利率風險利率風險係指債券","listText":"虎友，你好！喺上節課中，我哋主要探討了債券嘅定義和分類，並瞭解了債券嘅五個基本要素。呢節課，我將帶你學習：點解要投資美國國債以及投資風險。此外，我還會手把手教你點樣計算美國國債嘅回報。一、點解要投資美國國債許多虎友可能會講，與股票、期權等資產相比，美國國債嘅回報太低，感覺冇乜吸引力。梗系，如果只睇未嚟嘅潛喺回報率，債券似乎確實唔咁吸引人。但從長期資產配置和風險管理嘅角度嚟睇，美國國債具有三個獨特嘅優點：1、投資門檻低唔同於許多其他需要高起點投資嘅債券產品，喺 老虎證券app 上，購買債券嘅門檻非常低。以美國國債為例，目前喺老虎證券app上，最低只需1000美元就可以投資國債。此外，購買國債嘅交易過程非常簡單，類似於購買股票，我將喺最後一課詳細介紹交易步驟。2、風險較低相對於股票、期權等資產，債券嘅風險較低。如果你購買嘅系像美國國債呢種具有主權背書嘅債券，基本上唔會面臨信用風險。畢竟，迄今為止，美國國債從未發生過信用違約。3、收益穩健債券提供固定嘅票息，只要持有，就可以按期獲得派息，唔受市場波動嘅影響，回報相對穩定。喺到期後，你還能拿回你嘅投資本金，呢非常適合啲唔願承擔高風險嘅投資者。二、債券投資嘅兩大風險盡管美國國債具有低門檻、低風險和穩定回報嘅特點，但仍然存在一些潛喺風險。除咗匯率因素外，投資債券主要會面臨兩種風險：信用風險和利率風險。1、信用風險信用風險係指債券發行者無法按時償還本金或支付利息嘅風險。信用風險對債券嘅影響非常重要，因為佢直接影響着債券嘅價格和投資回報。一般嚟講，信用質量較高嘅債券通常具有較低嘅回報率，而信用質量較低嘅債券通常具有較高嘅回報率。像養老金基金和保險公司呢類機構投資者，通常更傾向於持有高信用債券，因為佢哋更加關注本金和穩定嘅利息支付。另一些機構投資者，如高收益債券基金，可能更傾向於尋求較高回報，肯承擔較高嘅信用風險。2、利率風險利率風險係指債券","text":"虎友，你好！喺上節課中，我哋主要探討了債券嘅定義和分類，並瞭解了債券嘅五個基本要素。呢節課，我將帶你學習：點解要投資美國國債以及投資風險。此外，我還會手把手教你點樣計算美國國債嘅回報。一、點解要投資美國國債許多虎友可能會講，與股票、期權等資產相比，美國國債嘅回報太低，感覺冇乜吸引力。梗系，如果只睇未嚟嘅潛喺回報率，債券似乎確實唔咁吸引人。但從長期資產配置和風險管理嘅角度嚟睇，美國國債具有三個獨特嘅優點：1、投資門檻低唔同於許多其他需要高起點投資嘅債券產品，喺 老虎證券app 上，購買債券嘅門檻非常低。以美國國債為例，目前喺老虎證券app上，最低只需1000美元就可以投資國債。此外，購買國債嘅交易過程非常簡單，類似於購買股票，我將喺最後一課詳細介紹交易步驟。2、風險較低相對於股票、期權等資產，債券嘅風險較低。如果你購買嘅系像美國國債呢種具有主權背書嘅債券，基本上唔會面臨信用風險。畢竟，迄今為止，美國國債從未發生過信用違約。3、收益穩健債券提供固定嘅票息，只要持有，就可以按期獲得派息，唔受市場波動嘅影響，回報相對穩定。喺到期後，你還能拿回你嘅投資本金，呢非常適合啲唔願承擔高風險嘅投資者。二、債券投資嘅兩大風險盡管美國國債具有低門檻、低風險和穩定回報嘅特點，但仍然存在一些潛喺風險。除咗匯率因素外，投資債券主要會面臨兩種風險：信用風險和利率風險。1、信用風險信用風險係指債券發行者無法按時償還本金或支付利息嘅風險。信用風險對債券嘅影響非常重要，因為佢直接影響着債券嘅價格和投資回報。一般嚟講，信用質量較高嘅債券通常具有較低嘅回報率，而信用質量較低嘅債券通常具有較高嘅回報率。像養老金基金和保險公司呢類機構投資者，通常更傾向於持有高信用債券，因為佢哋更加關注本金和穩定嘅利息支付。另一些機構投資者，如高收益債券基金，可能更傾向於尋求較高回報，肯承擔較高嘅信用風險。2、利率風險利率風險係指債券","images":[{"img":"https://community-static.tradeup.com/news/53c7e0e4cfec29784f43b0b0e395c3c7","width":"1280","height":"720"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/296191808987136","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":306182203072560,"gmtCreate":1715786675733,"gmtModify":1715788007084,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"title":"Cheers to a great start!","htmlText":"Find out more here: <a href=\"https://www.tigerbrokers.com.sg/activity/forapp/welcome/sgp.html?adcode=AC1713167566154PhgMAh&amp;is_invite=true&amp;utm_source=invite&amp;utm_campaign=AC1713171607756uKaqcQ&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=bc7c0bb9bd9abe98f9ba73f873c804a2&amp;invite=OOMW2C&amp;lang=en_US\">Cheers to a great start!</a> Receive rewards up to USD 3600*","listText":"Find out more here: <a href=\"https://www.tigerbrokers.com.sg/activity/forapp/welcome/sgp.html?adcode=AC1713167566154PhgMAh&amp;is_invite=true&amp;utm_source=invite&amp;utm_campaign=AC1713171607756uKaqcQ&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=bc7c0bb9bd9abe98f9ba73f873c804a2&amp;invite=OOMW2C&amp;lang=en_US\">Cheers to a great start!</a> Receive rewards up to USD 3600*","text":"Find out more here: Cheers to a great start! Receive rewards up to USD 3600*","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/306182203072560","isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":305793430630696,"gmtCreate":1715681761463,"gmtModify":1715681764809,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/305793430630696","repostId":"1165208547","repostType":2,"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304670426075224,"gmtCreate":1715417012665,"gmtModify":1715417016300,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304670426075224","repostId":"1158858114","repostType":2,"repost":{"id":"1158858114","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings","home_visible":1,"media_name":"TigerNews SG","id":"1050470178","head_image":"https://community-static.tradeup.com/news/f17a9a7b68c877792d5e556261e9e709"},"pubTimestamp":1715044134,"share":"https://www.laohu8.com/m/news/1158858114?lang=&edition=full","pubTime":"2024-05-07 09:08","market":"sg","language":"en","title":"SG Morning Call | STI Rose 0.02%, SIA Rose 1%, Singtel Rose 0.8%, SATS LTD Rose 0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158858114","media":"TigerNews SG","summary":"Stocks to WatchFrasers Logistics & Commercial Trust : BUOU (FLCT): Its distribution per unit (DPU) for the first half of the fiscal year declined 1.1 per cent to S$0.0348, reported its manager on Tues","content":"<html><head></head><body><h2 id=\"id_2780928662\">Market Snapshot</h2><p>Singapore stocks opened higher on Tuesday. STI rose 0.02%, Singtel rose 0.8%, SIA rose 1%, SATS LTD rose 0.8%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/5874359904a8061de27a065fddf2b293\" tg-width=\"307\" tg-height=\"558\"/></p><h2 id=\"id_3813175564\">Stocks to Watch</h2><p><strong>Frasers Logistics &amp; Commercial Trust : BUOU</strong> (FLCT): Its distribution per unit (DPU) for the first half of the fiscal year declined 1.1 per cent to S$0.0348, reported its manager on Tuesday. Though the Reit’s topline grew year on year, this was offset in part by higher vacancies, property operating expenses and finance costs. FLCT units ended Monday S$0.01 or 1 per cent up at S$1.01.</p><p style=\"text-align: start;\"><strong>Paragon Real Estate Investment Trust : SK6U</strong> (Reit): Its gross revenue for the first quarter ended March increased 3 per cent year on year to S$73.8 million. The growth was mainly driven by contributions from Paragon and The Clementi Mall, announced its manager on Monday. Units of Paragon Reit ended down S$0.005 or 0.6 per cent at S$0.84, before the announcement.</p><p style=\"text-align: start;\"><strong>Aims Apac Reit : O5RU</strong> (AA Reit): The industrial and logistics Reit’s DPU for the second half ended March fell 10.2 per cent to S$0.0471 from S$0.05244 a year prior on an enlarged unit base, reported its manager on Tuesday. This was despite an increase in gross revenue and net property income for the period. Units of AA Reit closed S$0.02 or 1.6 per cent higher at S$1.27 on Monday.</p><p style=\"text-align: start;\"><strong>Lendlease Global Reit : JYEU</strong>: Its manager on Monday reported a committed portfolio occupancy of 88.8 per cent for the third quarter ended Mar 31, 2024, up from 87.9 per cent in the previous quarter. Units of Lendlease Global Commercial Reit rose S$0.015 or 2.8 per cent to end at S$0.55, prior to the release of its business update for the quarter. </p><p style=\"text-align: start;\"><strong>Far East Orchard : O10</strong> (FEOR): The hotel operator and property developer, along with its subsidiaries, are selling Rendezvous Hotel Perth Central and its business for A$18.5 million (S$16.5 million). On Monday, FEOR said the disposal will enable the group to realise the value of the hotel, and in turn, improve capital allocation and optimise returns for the company’s shareholders. Shares of Far East Orchard closed flat at S$1.02, before the news.</p><p><strong>Singapore Airlines : C6L</strong> (SIA): The national flag carrier has agreed to purchase 1,000 tonnes of sustainable aviation fuel from renewable fuel producer Neste. On Monday, SIA said this will make the group and its budget airline Scoot the first carriers to receive sustainable aviation fuel produced at Neste’s Singapore refinery. The counter ended Monday at S$6.55, up S$0.03 or 0.5 per cent, prior to the announcement.</p><p style=\"text-align: start;\"><strong>Cordlife Group : P8A</strong>: The cord-blood bank’s directors have offered different views on who will oversee the company’s ongoing developments in Singapore. This was in response to queries from the Singapore Exchange (SGX) ahead of the company’s May 14 annual general meeting. Shares of Cordlife ended Monday flat at S$0.12, before the latest bourse filing was released. </p><h2 id=\"id_3059161784\">SG Local News</h2><h3 id=\"id_889847050\">SIA and Scoot First Airlines to Get Neste&#39;s SingaporE-made Sustainable Fuel at Changi Airport</h3><p>The Singapore Airlines (SIA) Group has signed an agreement with refinery Neste to purchase 1,000 tonnes of neat Neste MY Sustainable Aviation Fuel for airlines SIA and Scoot. </p><p>This will make the two airlines the first operating out of Changi Airport to receive sustainable aviation fuel (SAF) produced by Neste in Singapore, said SIA, Scoot and Neste in a joint media release on Monday (May 6).</p><h3 id=\"id_2633184637\">Jefferies Asks Judge to Remove Managers of Weiss Multi-Strategy</h3><p>MANAGERS of Weiss Multi-Strategy Advisers are trying to use the company’s bankruptcy case to enrich themselves and should be replaced by a court-approved trustee, Jefferies Financial Group said in a court filing.</p><p style=\"text-align: start;\">The move comes days after Weiss filed for court protection and sued Jefferies in US bankruptcy court in Manhattan. The defunct hedge fund is seeking to recover US$20 million, alleging the money either wrongly went to Jefferies over other creditors or was obtained under the threat of litigation. Jefferies has denied the allegations and said Weiss is acting in bad faith.</p><h3 id=\"id_387927790\">Possible Class Action Lawsuit against Cordlife by Customers Could Take at Least 2 Years</h3><p>A REPRESENTATIVE action suit against beleaguered cord-blood bank Cordlife could take at least two years to conclude, should affected Cordlife customers decide to go through with such a lawsuit, said partners at law firm Withers KhattarWong.</p><p style=\"text-align: start;\">However, the law firm stressed that the case is at an early fact-gathering and consolidation stage, and that it is not recommending that customers take up such a representative action – also known as a class action-type suit – at this juncture.</p><p style=\"text-align: start;\">This comes after Withers KhattarWong held a town hall meeting for affected Cordlife customers on Friday (May 3). The discussion covered the possible legal actions they could take, as well as the stages that are likely to take place in a class-action lawsuit.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SG Morning Call | STI Rose 0.02%, SIA Rose 1%, Singtel Rose 0.8%, SATS LTD Rose 0.8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSG Morning Call | STI Rose 0.02%, SIA Rose 1%, Singtel Rose 0.8%, SATS LTD Rose 0.8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1050470178\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/f17a9a7b68c877792d5e556261e9e709);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">TigerNews SG </p>\n<p class=\"h-time\">2024-05-07 09:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><h2 id=\"id_2780928662\">Market Snapshot</h2><p>Singapore stocks opened higher on Tuesday. STI rose 0.02%, Singtel rose 0.8%, SIA rose 1%, SATS LTD rose 0.8%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/5874359904a8061de27a065fddf2b293\" tg-width=\"307\" tg-height=\"558\"/></p><h2 id=\"id_3813175564\">Stocks to Watch</h2><p><strong>Frasers Logistics &amp; Commercial Trust : BUOU</strong> (FLCT): Its distribution per unit (DPU) for the first half of the fiscal year declined 1.1 per cent to S$0.0348, reported its manager on Tuesday. Though the Reit’s topline grew year on year, this was offset in part by higher vacancies, property operating expenses and finance costs. FLCT units ended Monday S$0.01 or 1 per cent up at S$1.01.</p><p style=\"text-align: start;\"><strong>Paragon Real Estate Investment Trust : SK6U</strong> (Reit): Its gross revenue for the first quarter ended March increased 3 per cent year on year to S$73.8 million. The growth was mainly driven by contributions from Paragon and The Clementi Mall, announced its manager on Monday. Units of Paragon Reit ended down S$0.005 or 0.6 per cent at S$0.84, before the announcement.</p><p style=\"text-align: start;\"><strong>Aims Apac Reit : O5RU</strong> (AA Reit): The industrial and logistics Reit’s DPU for the second half ended March fell 10.2 per cent to S$0.0471 from S$0.05244 a year prior on an enlarged unit base, reported its manager on Tuesday. This was despite an increase in gross revenue and net property income for the period. Units of AA Reit closed S$0.02 or 1.6 per cent higher at S$1.27 on Monday.</p><p style=\"text-align: start;\"><strong>Lendlease Global Reit : JYEU</strong>: Its manager on Monday reported a committed portfolio occupancy of 88.8 per cent for the third quarter ended Mar 31, 2024, up from 87.9 per cent in the previous quarter. Units of Lendlease Global Commercial Reit rose S$0.015 or 2.8 per cent to end at S$0.55, prior to the release of its business update for the quarter. </p><p style=\"text-align: start;\"><strong>Far East Orchard : O10</strong> (FEOR): The hotel operator and property developer, along with its subsidiaries, are selling Rendezvous Hotel Perth Central and its business for A$18.5 million (S$16.5 million). On Monday, FEOR said the disposal will enable the group to realise the value of the hotel, and in turn, improve capital allocation and optimise returns for the company’s shareholders. Shares of Far East Orchard closed flat at S$1.02, before the news.</p><p><strong>Singapore Airlines : C6L</strong> (SIA): The national flag carrier has agreed to purchase 1,000 tonnes of sustainable aviation fuel from renewable fuel producer Neste. On Monday, SIA said this will make the group and its budget airline Scoot the first carriers to receive sustainable aviation fuel produced at Neste’s Singapore refinery. The counter ended Monday at S$6.55, up S$0.03 or 0.5 per cent, prior to the announcement.</p><p style=\"text-align: start;\"><strong>Cordlife Group : P8A</strong>: The cord-blood bank’s directors have offered different views on who will oversee the company’s ongoing developments in Singapore. This was in response to queries from the Singapore Exchange (SGX) ahead of the company’s May 14 annual general meeting. Shares of Cordlife ended Monday flat at S$0.12, before the latest bourse filing was released. </p><h2 id=\"id_3059161784\">SG Local News</h2><h3 id=\"id_889847050\">SIA and Scoot First Airlines to Get Neste&#39;s SingaporE-made Sustainable Fuel at Changi Airport</h3><p>The Singapore Airlines (SIA) Group has signed an agreement with refinery Neste to purchase 1,000 tonnes of neat Neste MY Sustainable Aviation Fuel for airlines SIA and Scoot. </p><p>This will make the two airlines the first operating out of Changi Airport to receive sustainable aviation fuel (SAF) produced by Neste in Singapore, said SIA, Scoot and Neste in a joint media release on Monday (May 6).</p><h3 id=\"id_2633184637\">Jefferies Asks Judge to Remove Managers of Weiss Multi-Strategy</h3><p>MANAGERS of Weiss Multi-Strategy Advisers are trying to use the company’s bankruptcy case to enrich themselves and should be replaced by a court-approved trustee, Jefferies Financial Group said in a court filing.</p><p style=\"text-align: start;\">The move comes days after Weiss filed for court protection and sued Jefferies in US bankruptcy court in Manhattan. The defunct hedge fund is seeking to recover US$20 million, alleging the money either wrongly went to Jefferies over other creditors or was obtained under the threat of litigation. Jefferies has denied the allegations and said Weiss is acting in bad faith.</p><h3 id=\"id_387927790\">Possible Class Action Lawsuit against Cordlife by Customers Could Take at Least 2 Years</h3><p>A REPRESENTATIVE action suit against beleaguered cord-blood bank Cordlife could take at least two years to conclude, should affected Cordlife customers decide to go through with such a lawsuit, said partners at law firm Withers KhattarWong.</p><p style=\"text-align: start;\">However, the law firm stressed that the case is at an early fact-gathering and consolidation stage, and that it is not recommending that customers take up such a representative action – also known as a class action-type suit – at this juncture.</p><p style=\"text-align: start;\">This comes after Withers KhattarWong held a town hall meeting for affected Cordlife customers on Friday (May 3). The discussion covered the possible legal actions they could take, as well as the stages that are likely to take place in a class-action lawsuit.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"O10.SI":"远东乌节","SK6U.SI":"百利宫房地产投资信托","STI.SI":"富时新加坡海峡指数","C6L.SI":"新加坡航空公司","P8A.SI":"康盛人生","BUOU.SI":"星狮物流工业信托"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158858114","content_text":"Market SnapshotSingapore stocks opened higher on Tuesday. STI rose 0.02%, Singtel rose 0.8%, SIA rose 1%, SATS LTD rose 0.8%.Stocks to WatchFrasers Logistics & Commercial Trust : BUOU (FLCT): Its distribution per unit (DPU) for the first half of the fiscal year declined 1.1 per cent to S$0.0348, reported its manager on Tuesday. Though the Reit’s topline grew year on year, this was offset in part by higher vacancies, property operating expenses and finance costs. FLCT units ended Monday S$0.01 or 1 per cent up at S$1.01.Paragon Real Estate Investment Trust : SK6U (Reit): Its gross revenue for the first quarter ended March increased 3 per cent year on year to S$73.8 million. The growth was mainly driven by contributions from Paragon and The Clementi Mall, announced its manager on Monday. Units of Paragon Reit ended down S$0.005 or 0.6 per cent at S$0.84, before the announcement.Aims Apac Reit : O5RU (AA Reit): The industrial and logistics Reit’s DPU for the second half ended March fell 10.2 per cent to S$0.0471 from S$0.05244 a year prior on an enlarged unit base, reported its manager on Tuesday. This was despite an increase in gross revenue and net property income for the period. Units of AA Reit closed S$0.02 or 1.6 per cent higher at S$1.27 on Monday.Lendlease Global Reit : JYEU: Its manager on Monday reported a committed portfolio occupancy of 88.8 per cent for the third quarter ended Mar 31, 2024, up from 87.9 per cent in the previous quarter. Units of Lendlease Global Commercial Reit rose S$0.015 or 2.8 per cent to end at S$0.55, prior to the release of its business update for the quarter. Far East Orchard : O10 (FEOR): The hotel operator and property developer, along with its subsidiaries, are selling Rendezvous Hotel Perth Central and its business for A$18.5 million (S$16.5 million). On Monday, FEOR said the disposal will enable the group to realise the value of the hotel, and in turn, improve capital allocation and optimise returns for the company’s shareholders. Shares of Far East Orchard closed flat at S$1.02, before the news.Singapore Airlines : C6L (SIA): The national flag carrier has agreed to purchase 1,000 tonnes of sustainable aviation fuel from renewable fuel producer Neste. On Monday, SIA said this will make the group and its budget airline Scoot the first carriers to receive sustainable aviation fuel produced at Neste’s Singapore refinery. The counter ended Monday at S$6.55, up S$0.03 or 0.5 per cent, prior to the announcement.Cordlife Group : P8A: The cord-blood bank’s directors have offered different views on who will oversee the company’s ongoing developments in Singapore. This was in response to queries from the Singapore Exchange (SGX) ahead of the company’s May 14 annual general meeting. Shares of Cordlife ended Monday flat at S$0.12, before the latest bourse filing was released. SG Local NewsSIA and Scoot First Airlines to Get Neste's SingaporE-made Sustainable Fuel at Changi AirportThe Singapore Airlines (SIA) Group has signed an agreement with refinery Neste to purchase 1,000 tonnes of neat Neste MY Sustainable Aviation Fuel for airlines SIA and Scoot. This will make the two airlines the first operating out of Changi Airport to receive sustainable aviation fuel (SAF) produced by Neste in Singapore, said SIA, Scoot and Neste in a joint media release on Monday (May 6).Jefferies Asks Judge to Remove Managers of Weiss Multi-StrategyMANAGERS of Weiss Multi-Strategy Advisers are trying to use the company’s bankruptcy case to enrich themselves and should be replaced by a court-approved trustee, Jefferies Financial Group said in a court filing.The move comes days after Weiss filed for court protection and sued Jefferies in US bankruptcy court in Manhattan. The defunct hedge fund is seeking to recover US$20 million, alleging the money either wrongly went to Jefferies over other creditors or was obtained under the threat of litigation. Jefferies has denied the allegations and said Weiss is acting in bad faith.Possible Class Action Lawsuit against Cordlife by Customers Could Take at Least 2 YearsA REPRESENTATIVE action suit against beleaguered cord-blood bank Cordlife could take at least two years to conclude, should affected Cordlife customers decide to go through with such a lawsuit, said partners at law firm Withers KhattarWong.However, the law firm stressed that the case is at an early fact-gathering and consolidation stage, and that it is not recommending that customers take up such a representative action – also known as a class action-type suit – at this juncture.This comes after Withers KhattarWong held a town hall meeting for affected Cordlife customers on Friday (May 3). The discussion covered the possible legal actions they could take, as well as the stages that are likely to take place in a class-action lawsuit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304567189573672,"gmtCreate":1715391801861,"gmtModify":1715391803841,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/00728\">$CHINA TELECOM(00728)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/00728\">$CHINA TELECOM(00728)$</a>&nbsp;","text":"$CHINA TELECOM(00728)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304567189573672","isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304567468212488,"gmtCreate":1715391791829,"gmtModify":1715391795301,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/00728\">$CHINA TELECOM(00728)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/00728\">$CHINA TELECOM(00728)$</a>&nbsp;","text":"$CHINA TELECOM(00728)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304567468212488","isVote":1,"tweetType":1,"viewCount":73,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304503237988488,"gmtCreate":1715376197429,"gmtModify":1715376201251,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> <a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> <a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>&nbsp;","text":"$Tiger Brokers(TIGR)$ $BioNTech SE(BNTX)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304503237988488","isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304502816981280,"gmtCreate":1715376008170,"gmtModify":1715394730521,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;","text":"$Tiger Brokers(TIGR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304502816981280","isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304497930604720,"gmtCreate":1715374902608,"gmtModify":1715378953078,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/304497930604720","repostId":"2434844398","repostType":2,"repost":{"id":"2434844398","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1715338729,"share":"https://www.laohu8.com/m/news/2434844398?lang=&edition=full","pubTime":"2024-05-10 18:58","market":"us","language":"en","title":"Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability","url":"https://stock-news.laohu8.com/highlight/detail?id=2434844398","media":"Reuters","summary":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with $Sanofi(GCVRZ)$ for COVID-19 vaccines in exchange for a st","content":"<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-05-10 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4588":"碎股","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4007":"制药","SNY":"赛诺菲安万特","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","NVAX":"诺瓦瓦克斯医药","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SNYNF":"Sanofi"},"source_url":"https://finance.yahoo.com/news/1-frances-sanofi-covid-19-061951520.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2434844398","content_text":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker's market value.Novavax’s U.S.-listed shares soared over 202% in premarket trading.In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax's Matrix-M adjuvant.Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.\"We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)\", Sanofi's head of vaccines R&D, Jean-Francois Toussaint, said in a statement.Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D'Souza)","news_type":1},"isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304497975070864,"gmtCreate":1715374823986,"gmtModify":1715378950032,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304497975070864","repostId":"2434844398","repostType":2,"repost":{"id":"2434844398","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1715338729,"share":"https://www.laohu8.com/m/news/2434844398?lang=&edition=full","pubTime":"2024-05-10 18:58","market":"us","language":"en","title":"Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability","url":"https://stock-news.laohu8.com/highlight/detail?id=2434844398","media":"Reuters","summary":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with $Sanofi(GCVRZ)$ for COVID-19 vaccines in exchange for a st","content":"<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-05-10 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4588":"碎股","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4007":"制药","SNY":"赛诺菲安万特","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","NVAX":"诺瓦瓦克斯医药","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SNYNF":"Sanofi"},"source_url":"https://finance.yahoo.com/news/1-frances-sanofi-covid-19-061951520.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2434844398","content_text":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker's market value.Novavax’s U.S.-listed shares soared over 202% in premarket trading.In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax's Matrix-M adjuvant.Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.\"We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)\", Sanofi's head of vaccines R&D, Jean-Francois Toussaint, said in a statement.Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D'Souza)","news_type":1},"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304495767683312,"gmtCreate":1715374286171,"gmtModify":1715378943979,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"title":"Cheers to a great start!","htmlText":"Find out more here: <a href=\"https://www.tigerbrokers.com.sg/activity/forapp/welcome/sgp.html?adcode=AC1713167566154PhgMAh&amp;skin=1&amp;os=iOS&amp;account_id=20240509162636932&amp;is_invite=true&amp;utm_source=invite&amp;utm_campaign=AC1713171607756uKaqcQ&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=323ef2663e1378c2f4d76642b6e1f817&amp;invite=OOMW2C&amp;lang=en_US\">Cheers to a great start!</a> Receive rewards up to USD 3600*","listText":"Find out more here: <a href=\"https://www.tigerbrokers.com.sg/activity/forapp/welcome/sgp.html?adcode=AC1713167566154PhgMAh&amp;skin=1&amp;os=iOS&amp;account_id=20240509162636932&amp;is_invite=true&amp;utm_source=invite&amp;utm_campaign=AC1713171607756uKaqcQ&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=323ef2663e1378c2f4d76642b6e1f817&amp;invite=OOMW2C&amp;lang=en_US\">Cheers to a great start!</a> Receive rewards up to USD 3600*","text":"Find out more here: Cheers to a great start! Receive rewards up to USD 3600*","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304495767683312","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":304497930604720,"gmtCreate":1715374902608,"gmtModify":1715378953078,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/304497930604720","repostId":"2434844398","repostType":2,"repost":{"id":"2434844398","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1715338729,"share":"https://www.laohu8.com/m/news/2434844398?lang=&edition=full","pubTime":"2024-05-10 18:58","market":"us","language":"en","title":"Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability","url":"https://stock-news.laohu8.com/highlight/detail?id=2434844398","media":"Reuters","summary":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with $Sanofi(GCVRZ)$ for COVID-19 vaccines in exchange for a st","content":"<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-05-10 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4588":"碎股","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4007":"制药","SNY":"赛诺菲安万特","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","NVAX":"诺瓦瓦克斯医药","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SNYNF":"Sanofi"},"source_url":"https://finance.yahoo.com/news/1-frances-sanofi-covid-19-061951520.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2434844398","content_text":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker's market value.Novavax’s U.S.-listed shares soared over 202% in premarket trading.In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax's Matrix-M adjuvant.Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.\"We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)\", Sanofi's head of vaccines R&D, Jean-Francois Toussaint, said in a statement.Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D'Souza)","news_type":1},"isVote":1,"tweetType":1,"viewCount":74,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":305793430630696,"gmtCreate":1715681761463,"gmtModify":1715681764809,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/305793430630696","repostId":"1165208547","repostType":2,"repost":{"id":"1165208547","pubTimestamp":1715681607,"share":"https://www.laohu8.com/m/news/1165208547?lang=&edition=full","pubTime":"2024-05-14 18:13","market":"sg","language":"en","title":"STI up 0.3% Amid a Mixed Regional Showing","url":"https://stock-news.laohu8.com/highlight/detail?id=1165208547","media":"business times","summary":"SINGAPORE’S Straits Times Index was 0.3 per cent or 9.69 points higher at 3,313.35 points on Tuesday (May 14), against a mixed bag from regional bourses as market participants traded with caution befo","content":"<div>\n<p>SINGAPORE’S Straits Times Index was 0.3 per cent or 9.69 points higher at 3,313.35 points on Tuesday (May 14), against a mixed bag from regional bourses as market participants traded with caution ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/capital-markets-currencies/sti-0-3-amid-mixed-regional-showing\">Web Link</a>\n\n</div>\n","source":"bustime_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>STI up 0.3% Amid a Mixed Regional Showing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSTI up 0.3% Amid a Mixed Regional Showing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-14 18:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/companies-markets/capital-markets-currencies/sti-0-3-amid-mixed-regional-showing><strong>business times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE’S Straits Times Index was 0.3 per cent or 9.69 points higher at 3,313.35 points on Tuesday (May 14), against a mixed bag from regional bourses as market participants traded with caution ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/capital-markets-currencies/sti-0-3-amid-mixed-regional-showing\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.businesstimes.com.sg/companies-markets/capital-markets-currencies/sti-0-3-amid-mixed-regional-showing","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165208547","content_text":"SINGAPORE’S Straits Times Index was 0.3 per cent or 9.69 points higher at 3,313.35 points on Tuesday (May 14), against a mixed bag from regional bourses as market participants traded with caution before the United States’ release of its inflation figures mid-week.The consumer price index and producer price index are anticipated to play a crucial role in shaping the outlook for Federal Reserve policy, contributing to the market’s cautious stance, said Stephen Innes, SPI Asset Management’s managing partner.Investors are particularly sensitive to the inflation data, given its potential to influence interest-rate decisions and the broader market sentiment. Therefore, market participants are likely to tread carefully, awaiting clearer signals from the inflation figures before making significant moves, he pointed out.This week’s data dump wags two significant tail risks: one tied to warmer inflation concerns and the other linked to slower economy activity, raising fears of stagflation. In either scenario, the market response could be unfavourable. Investors have thus remained cautious, as either outcome could trigger a broader stock market sell-off.“You wouldn’t want to find yourself in a crowded index theatre with investors screaming about inflation or stagflation while dashing for the fire exits,” Innes quipped.Singapore Technologies Engineering (ST Engineering) : S63 shares reached a 52-week high at S$4.20, up 4.2 per cent or S$0.17, a day after the group delivered an 18.1 per cent rise in revenue to S$2.7 billion, and bagged S$3 billion in new orders for the first quarter to March. The STI’s best performer’s financial performance was within the expectations of analysts.The shares of semiconductor equipment manufacturer UMS Holdings : 558 were down a further 4.5 per cent or S$0.05 to S$1.06, after having plunged 15.9 per cent on Monday on the back of its first-quarter net profit’s decline of 44 per cent to S$9.8 million.Across the broader market, gainers beat decliners 357 to 225, with 1.21 billion of securities transacted at a total value of about S$1.2 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":102,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":306188966731800,"gmtCreate":1715788413641,"gmtModify":1715788415788,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/306188966731800","repostId":"296191808987136","repostType":1,"repost":{"id":296191808987136,"gmtCreate":1713323138862,"gmtModify":1713334657534,"author":{"id":"4104455119105420","authorId":"4104455119105420","name":"Tiger_Academy","avatar":"https://static.tigerbbs.com/3776fe550cd7a945e43d68c025988ed8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"第二課：投資美國國債嘅優勢和風險","htmlText":"虎友，你好！喺上節課中，我哋主要探討了債券嘅定義和分類，並瞭解了債券嘅五個基本要素。呢節課，我將帶你學習：點解要投資美國國債以及投資風險。此外，我還會手把手教你點樣計算美國國債嘅回報。一、點解要投資美國國債許多虎友可能會講，與股票、期權等資產相比，美國國債嘅回報太低，感覺冇乜吸引力。梗系，如果只睇未嚟嘅潛喺回報率，債券似乎確實唔咁吸引人。但從長期資產配置和風險管理嘅角度嚟睇，美國國債具有三個獨特嘅優點：1、投資門檻低唔同於許多其他需要高起點投資嘅債券產品，喺 老虎證券app 上，購買債券嘅門檻非常低。以美國國債為例，目前喺老虎證券app上，最低只需1000美元就可以投資國債。此外，購買國債嘅交易過程非常簡單，類似於購買股票，我將喺最後一課詳細介紹交易步驟。2、風險較低相對於股票、期權等資產，債券嘅風險較低。如果你購買嘅系像美國國債呢種具有主權背書嘅債券，基本上唔會面臨信用風險。畢竟，迄今為止，美國國債從未發生過信用違約。3、收益穩健債券提供固定嘅票息，只要持有，就可以按期獲得派息，唔受市場波動嘅影響，回報相對穩定。喺到期後，你還能拿回你嘅投資本金，呢非常適合啲唔願承擔高風險嘅投資者。二、債券投資嘅兩大風險盡管美國國債具有低門檻、低風險和穩定回報嘅特點，但仍然存在一些潛喺風險。除咗匯率因素外，投資債券主要會面臨兩種風險：信用風險和利率風險。1、信用風險信用風險係指債券發行者無法按時償還本金或支付利息嘅風險。信用風險對債券嘅影響非常重要，因為佢直接影響着債券嘅價格和投資回報。一般嚟講，信用質量較高嘅債券通常具有較低嘅回報率，而信用質量較低嘅債券通常具有較高嘅回報率。像養老金基金和保險公司呢類機構投資者，通常更傾向於持有高信用債券，因為佢哋更加關注本金和穩定嘅利息支付。另一些機構投資者，如高收益債券基金，可能更傾向於尋求較高回報，肯承擔較高嘅信用風險。2、利率風險利率風險係指債券","listText":"虎友，你好！喺上節課中，我哋主要探討了債券嘅定義和分類，並瞭解了債券嘅五個基本要素。呢節課，我將帶你學習：點解要投資美國國債以及投資風險。此外，我還會手把手教你點樣計算美國國債嘅回報。一、點解要投資美國國債許多虎友可能會講，與股票、期權等資產相比，美國國債嘅回報太低，感覺冇乜吸引力。梗系，如果只睇未嚟嘅潛喺回報率，債券似乎確實唔咁吸引人。但從長期資產配置和風險管理嘅角度嚟睇，美國國債具有三個獨特嘅優點：1、投資門檻低唔同於許多其他需要高起點投資嘅債券產品，喺 老虎證券app 上，購買債券嘅門檻非常低。以美國國債為例，目前喺老虎證券app上，最低只需1000美元就可以投資國債。此外，購買國債嘅交易過程非常簡單，類似於購買股票，我將喺最後一課詳細介紹交易步驟。2、風險較低相對於股票、期權等資產，債券嘅風險較低。如果你購買嘅系像美國國債呢種具有主權背書嘅債券，基本上唔會面臨信用風險。畢竟，迄今為止，美國國債從未發生過信用違約。3、收益穩健債券提供固定嘅票息，只要持有，就可以按期獲得派息，唔受市場波動嘅影響，回報相對穩定。喺到期後，你還能拿回你嘅投資本金，呢非常適合啲唔願承擔高風險嘅投資者。二、債券投資嘅兩大風險盡管美國國債具有低門檻、低風險和穩定回報嘅特點，但仍然存在一些潛喺風險。除咗匯率因素外，投資債券主要會面臨兩種風險：信用風險和利率風險。1、信用風險信用風險係指債券發行者無法按時償還本金或支付利息嘅風險。信用風險對債券嘅影響非常重要，因為佢直接影響着債券嘅價格和投資回報。一般嚟講，信用質量較高嘅債券通常具有較低嘅回報率，而信用質量較低嘅債券通常具有較高嘅回報率。像養老金基金和保險公司呢類機構投資者，通常更傾向於持有高信用債券，因為佢哋更加關注本金和穩定嘅利息支付。另一些機構投資者，如高收益債券基金，可能更傾向於尋求較高回報，肯承擔較高嘅信用風險。2、利率風險利率風險係指債券","text":"虎友，你好！喺上節課中，我哋主要探討了債券嘅定義和分類，並瞭解了債券嘅五個基本要素。呢節課，我將帶你學習：點解要投資美國國債以及投資風險。此外，我還會手把手教你點樣計算美國國債嘅回報。一、點解要投資美國國債許多虎友可能會講，與股票、期權等資產相比，美國國債嘅回報太低，感覺冇乜吸引力。梗系，如果只睇未嚟嘅潛喺回報率，債券似乎確實唔咁吸引人。但從長期資產配置和風險管理嘅角度嚟睇，美國國債具有三個獨特嘅優點：1、投資門檻低唔同於許多其他需要高起點投資嘅債券產品，喺 老虎證券app 上，購買債券嘅門檻非常低。以美國國債為例，目前喺老虎證券app上，最低只需1000美元就可以投資國債。此外，購買國債嘅交易過程非常簡單，類似於購買股票，我將喺最後一課詳細介紹交易步驟。2、風險較低相對於股票、期權等資產，債券嘅風險較低。如果你購買嘅系像美國國債呢種具有主權背書嘅債券，基本上唔會面臨信用風險。畢竟，迄今為止，美國國債從未發生過信用違約。3、收益穩健債券提供固定嘅票息，只要持有，就可以按期獲得派息，唔受市場波動嘅影響，回報相對穩定。喺到期後，你還能拿回你嘅投資本金，呢非常適合啲唔願承擔高風險嘅投資者。二、債券投資嘅兩大風險盡管美國國債具有低門檻、低風險和穩定回報嘅特點，但仍然存在一些潛喺風險。除咗匯率因素外，投資債券主要會面臨兩種風險：信用風險和利率風險。1、信用風險信用風險係指債券發行者無法按時償還本金或支付利息嘅風險。信用風險對債券嘅影響非常重要，因為佢直接影響着債券嘅價格和投資回報。一般嚟講，信用質量較高嘅債券通常具有較低嘅回報率，而信用質量較低嘅債券通常具有較高嘅回報率。像養老金基金和保險公司呢類機構投資者，通常更傾向於持有高信用債券，因為佢哋更加關注本金和穩定嘅利息支付。另一些機構投資者，如高收益債券基金，可能更傾向於尋求較高回報，肯承擔較高嘅信用風險。2、利率風險利率風險係指債券","images":[{"img":"https://community-static.tradeup.com/news/53c7e0e4cfec29784f43b0b0e395c3c7","width":"1280","height":"720"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/296191808987136","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":306182203072560,"gmtCreate":1715786675733,"gmtModify":1715788007084,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"title":"Cheers to a great start!","htmlText":"Find out more here: <a href=\"https://www.tigerbrokers.com.sg/activity/forapp/welcome/sgp.html?adcode=AC1713167566154PhgMAh&amp;is_invite=true&amp;utm_source=invite&amp;utm_campaign=AC1713171607756uKaqcQ&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=bc7c0bb9bd9abe98f9ba73f873c804a2&amp;invite=OOMW2C&amp;lang=en_US\">Cheers to a great start!</a> Receive rewards up to USD 3600*","listText":"Find out more here: <a href=\"https://www.tigerbrokers.com.sg/activity/forapp/welcome/sgp.html?adcode=AC1713167566154PhgMAh&amp;is_invite=true&amp;utm_source=invite&amp;utm_campaign=AC1713171607756uKaqcQ&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=bc7c0bb9bd9abe98f9ba73f873c804a2&amp;invite=OOMW2C&amp;lang=en_US\">Cheers to a great start!</a> Receive rewards up to USD 3600*","text":"Find out more here: Cheers to a great start! Receive rewards up to USD 3600*","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/306182203072560","isVote":1,"tweetType":1,"viewCount":48,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304670426075224,"gmtCreate":1715417012665,"gmtModify":1715417016300,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304670426075224","repostId":"1158858114","repostType":2,"repost":{"id":"1158858114","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings","home_visible":1,"media_name":"TigerNews SG","id":"1050470178","head_image":"https://community-static.tradeup.com/news/f17a9a7b68c877792d5e556261e9e709"},"pubTimestamp":1715044134,"share":"https://www.laohu8.com/m/news/1158858114?lang=&edition=full","pubTime":"2024-05-07 09:08","market":"sg","language":"en","title":"SG Morning Call | STI Rose 0.02%, SIA Rose 1%, Singtel Rose 0.8%, SATS LTD Rose 0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158858114","media":"TigerNews SG","summary":"Stocks to WatchFrasers Logistics & Commercial Trust : BUOU (FLCT): Its distribution per unit (DPU) for the first half of the fiscal year declined 1.1 per cent to S$0.0348, reported its manager on Tues","content":"<html><head></head><body><h2 id=\"id_2780928662\">Market Snapshot</h2><p>Singapore stocks opened higher on Tuesday. STI rose 0.02%, Singtel rose 0.8%, SIA rose 1%, SATS LTD rose 0.8%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/5874359904a8061de27a065fddf2b293\" tg-width=\"307\" tg-height=\"558\"/></p><h2 id=\"id_3813175564\">Stocks to Watch</h2><p><strong>Frasers Logistics &amp; Commercial Trust : BUOU</strong> (FLCT): Its distribution per unit (DPU) for the first half of the fiscal year declined 1.1 per cent to S$0.0348, reported its manager on Tuesday. Though the Reit’s topline grew year on year, this was offset in part by higher vacancies, property operating expenses and finance costs. FLCT units ended Monday S$0.01 or 1 per cent up at S$1.01.</p><p style=\"text-align: start;\"><strong>Paragon Real Estate Investment Trust : SK6U</strong> (Reit): Its gross revenue for the first quarter ended March increased 3 per cent year on year to S$73.8 million. The growth was mainly driven by contributions from Paragon and The Clementi Mall, announced its manager on Monday. Units of Paragon Reit ended down S$0.005 or 0.6 per cent at S$0.84, before the announcement.</p><p style=\"text-align: start;\"><strong>Aims Apac Reit : O5RU</strong> (AA Reit): The industrial and logistics Reit’s DPU for the second half ended March fell 10.2 per cent to S$0.0471 from S$0.05244 a year prior on an enlarged unit base, reported its manager on Tuesday. This was despite an increase in gross revenue and net property income for the period. Units of AA Reit closed S$0.02 or 1.6 per cent higher at S$1.27 on Monday.</p><p style=\"text-align: start;\"><strong>Lendlease Global Reit : JYEU</strong>: Its manager on Monday reported a committed portfolio occupancy of 88.8 per cent for the third quarter ended Mar 31, 2024, up from 87.9 per cent in the previous quarter. Units of Lendlease Global Commercial Reit rose S$0.015 or 2.8 per cent to end at S$0.55, prior to the release of its business update for the quarter. </p><p style=\"text-align: start;\"><strong>Far East Orchard : O10</strong> (FEOR): The hotel operator and property developer, along with its subsidiaries, are selling Rendezvous Hotel Perth Central and its business for A$18.5 million (S$16.5 million). On Monday, FEOR said the disposal will enable the group to realise the value of the hotel, and in turn, improve capital allocation and optimise returns for the company’s shareholders. Shares of Far East Orchard closed flat at S$1.02, before the news.</p><p><strong>Singapore Airlines : C6L</strong> (SIA): The national flag carrier has agreed to purchase 1,000 tonnes of sustainable aviation fuel from renewable fuel producer Neste. On Monday, SIA said this will make the group and its budget airline Scoot the first carriers to receive sustainable aviation fuel produced at Neste’s Singapore refinery. The counter ended Monday at S$6.55, up S$0.03 or 0.5 per cent, prior to the announcement.</p><p style=\"text-align: start;\"><strong>Cordlife Group : P8A</strong>: The cord-blood bank’s directors have offered different views on who will oversee the company’s ongoing developments in Singapore. This was in response to queries from the Singapore Exchange (SGX) ahead of the company’s May 14 annual general meeting. Shares of Cordlife ended Monday flat at S$0.12, before the latest bourse filing was released. </p><h2 id=\"id_3059161784\">SG Local News</h2><h3 id=\"id_889847050\">SIA and Scoot First Airlines to Get Neste&#39;s SingaporE-made Sustainable Fuel at Changi Airport</h3><p>The Singapore Airlines (SIA) Group has signed an agreement with refinery Neste to purchase 1,000 tonnes of neat Neste MY Sustainable Aviation Fuel for airlines SIA and Scoot. </p><p>This will make the two airlines the first operating out of Changi Airport to receive sustainable aviation fuel (SAF) produced by Neste in Singapore, said SIA, Scoot and Neste in a joint media release on Monday (May 6).</p><h3 id=\"id_2633184637\">Jefferies Asks Judge to Remove Managers of Weiss Multi-Strategy</h3><p>MANAGERS of Weiss Multi-Strategy Advisers are trying to use the company’s bankruptcy case to enrich themselves and should be replaced by a court-approved trustee, Jefferies Financial Group said in a court filing.</p><p style=\"text-align: start;\">The move comes days after Weiss filed for court protection and sued Jefferies in US bankruptcy court in Manhattan. The defunct hedge fund is seeking to recover US$20 million, alleging the money either wrongly went to Jefferies over other creditors or was obtained under the threat of litigation. Jefferies has denied the allegations and said Weiss is acting in bad faith.</p><h3 id=\"id_387927790\">Possible Class Action Lawsuit against Cordlife by Customers Could Take at Least 2 Years</h3><p>A REPRESENTATIVE action suit against beleaguered cord-blood bank Cordlife could take at least two years to conclude, should affected Cordlife customers decide to go through with such a lawsuit, said partners at law firm Withers KhattarWong.</p><p style=\"text-align: start;\">However, the law firm stressed that the case is at an early fact-gathering and consolidation stage, and that it is not recommending that customers take up such a representative action – also known as a class action-type suit – at this juncture.</p><p style=\"text-align: start;\">This comes after Withers KhattarWong held a town hall meeting for affected Cordlife customers on Friday (May 3). The discussion covered the possible legal actions they could take, as well as the stages that are likely to take place in a class-action lawsuit.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SG Morning Call | STI Rose 0.02%, SIA Rose 1%, Singtel Rose 0.8%, SATS LTD Rose 0.8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSG Morning Call | STI Rose 0.02%, SIA Rose 1%, Singtel Rose 0.8%, SATS LTD Rose 0.8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1050470178\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/f17a9a7b68c877792d5e556261e9e709);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">TigerNews SG </p>\n<p class=\"h-time\">2024-05-07 09:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><h2 id=\"id_2780928662\">Market Snapshot</h2><p>Singapore stocks opened higher on Tuesday. STI rose 0.02%, Singtel rose 0.8%, SIA rose 1%, SATS LTD rose 0.8%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/5874359904a8061de27a065fddf2b293\" tg-width=\"307\" tg-height=\"558\"/></p><h2 id=\"id_3813175564\">Stocks to Watch</h2><p><strong>Frasers Logistics &amp; Commercial Trust : BUOU</strong> (FLCT): Its distribution per unit (DPU) for the first half of the fiscal year declined 1.1 per cent to S$0.0348, reported its manager on Tuesday. Though the Reit’s topline grew year on year, this was offset in part by higher vacancies, property operating expenses and finance costs. FLCT units ended Monday S$0.01 or 1 per cent up at S$1.01.</p><p style=\"text-align: start;\"><strong>Paragon Real Estate Investment Trust : SK6U</strong> (Reit): Its gross revenue for the first quarter ended March increased 3 per cent year on year to S$73.8 million. The growth was mainly driven by contributions from Paragon and The Clementi Mall, announced its manager on Monday. Units of Paragon Reit ended down S$0.005 or 0.6 per cent at S$0.84, before the announcement.</p><p style=\"text-align: start;\"><strong>Aims Apac Reit : O5RU</strong> (AA Reit): The industrial and logistics Reit’s DPU for the second half ended March fell 10.2 per cent to S$0.0471 from S$0.05244 a year prior on an enlarged unit base, reported its manager on Tuesday. This was despite an increase in gross revenue and net property income for the period. Units of AA Reit closed S$0.02 or 1.6 per cent higher at S$1.27 on Monday.</p><p style=\"text-align: start;\"><strong>Lendlease Global Reit : JYEU</strong>: Its manager on Monday reported a committed portfolio occupancy of 88.8 per cent for the third quarter ended Mar 31, 2024, up from 87.9 per cent in the previous quarter. Units of Lendlease Global Commercial Reit rose S$0.015 or 2.8 per cent to end at S$0.55, prior to the release of its business update for the quarter. </p><p style=\"text-align: start;\"><strong>Far East Orchard : O10</strong> (FEOR): The hotel operator and property developer, along with its subsidiaries, are selling Rendezvous Hotel Perth Central and its business for A$18.5 million (S$16.5 million). On Monday, FEOR said the disposal will enable the group to realise the value of the hotel, and in turn, improve capital allocation and optimise returns for the company’s shareholders. Shares of Far East Orchard closed flat at S$1.02, before the news.</p><p><strong>Singapore Airlines : C6L</strong> (SIA): The national flag carrier has agreed to purchase 1,000 tonnes of sustainable aviation fuel from renewable fuel producer Neste. On Monday, SIA said this will make the group and its budget airline Scoot the first carriers to receive sustainable aviation fuel produced at Neste’s Singapore refinery. The counter ended Monday at S$6.55, up S$0.03 or 0.5 per cent, prior to the announcement.</p><p style=\"text-align: start;\"><strong>Cordlife Group : P8A</strong>: The cord-blood bank’s directors have offered different views on who will oversee the company’s ongoing developments in Singapore. This was in response to queries from the Singapore Exchange (SGX) ahead of the company’s May 14 annual general meeting. Shares of Cordlife ended Monday flat at S$0.12, before the latest bourse filing was released. </p><h2 id=\"id_3059161784\">SG Local News</h2><h3 id=\"id_889847050\">SIA and Scoot First Airlines to Get Neste&#39;s SingaporE-made Sustainable Fuel at Changi Airport</h3><p>The Singapore Airlines (SIA) Group has signed an agreement with refinery Neste to purchase 1,000 tonnes of neat Neste MY Sustainable Aviation Fuel for airlines SIA and Scoot. </p><p>This will make the two airlines the first operating out of Changi Airport to receive sustainable aviation fuel (SAF) produced by Neste in Singapore, said SIA, Scoot and Neste in a joint media release on Monday (May 6).</p><h3 id=\"id_2633184637\">Jefferies Asks Judge to Remove Managers of Weiss Multi-Strategy</h3><p>MANAGERS of Weiss Multi-Strategy Advisers are trying to use the company’s bankruptcy case to enrich themselves and should be replaced by a court-approved trustee, Jefferies Financial Group said in a court filing.</p><p style=\"text-align: start;\">The move comes days after Weiss filed for court protection and sued Jefferies in US bankruptcy court in Manhattan. The defunct hedge fund is seeking to recover US$20 million, alleging the money either wrongly went to Jefferies over other creditors or was obtained under the threat of litigation. Jefferies has denied the allegations and said Weiss is acting in bad faith.</p><h3 id=\"id_387927790\">Possible Class Action Lawsuit against Cordlife by Customers Could Take at Least 2 Years</h3><p>A REPRESENTATIVE action suit against beleaguered cord-blood bank Cordlife could take at least two years to conclude, should affected Cordlife customers decide to go through with such a lawsuit, said partners at law firm Withers KhattarWong.</p><p style=\"text-align: start;\">However, the law firm stressed that the case is at an early fact-gathering and consolidation stage, and that it is not recommending that customers take up such a representative action – also known as a class action-type suit – at this juncture.</p><p style=\"text-align: start;\">This comes after Withers KhattarWong held a town hall meeting for affected Cordlife customers on Friday (May 3). The discussion covered the possible legal actions they could take, as well as the stages that are likely to take place in a class-action lawsuit.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"O10.SI":"远东乌节","SK6U.SI":"百利宫房地产投资信托","STI.SI":"富时新加坡海峡指数","C6L.SI":"新加坡航空公司","P8A.SI":"康盛人生","BUOU.SI":"星狮物流工业信托"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158858114","content_text":"Market SnapshotSingapore stocks opened higher on Tuesday. STI rose 0.02%, Singtel rose 0.8%, SIA rose 1%, SATS LTD rose 0.8%.Stocks to WatchFrasers Logistics & Commercial Trust : BUOU (FLCT): Its distribution per unit (DPU) for the first half of the fiscal year declined 1.1 per cent to S$0.0348, reported its manager on Tuesday. Though the Reit’s topline grew year on year, this was offset in part by higher vacancies, property operating expenses and finance costs. FLCT units ended Monday S$0.01 or 1 per cent up at S$1.01.Paragon Real Estate Investment Trust : SK6U (Reit): Its gross revenue for the first quarter ended March increased 3 per cent year on year to S$73.8 million. The growth was mainly driven by contributions from Paragon and The Clementi Mall, announced its manager on Monday. Units of Paragon Reit ended down S$0.005 or 0.6 per cent at S$0.84, before the announcement.Aims Apac Reit : O5RU (AA Reit): The industrial and logistics Reit’s DPU for the second half ended March fell 10.2 per cent to S$0.0471 from S$0.05244 a year prior on an enlarged unit base, reported its manager on Tuesday. This was despite an increase in gross revenue and net property income for the period. Units of AA Reit closed S$0.02 or 1.6 per cent higher at S$1.27 on Monday.Lendlease Global Reit : JYEU: Its manager on Monday reported a committed portfolio occupancy of 88.8 per cent for the third quarter ended Mar 31, 2024, up from 87.9 per cent in the previous quarter. Units of Lendlease Global Commercial Reit rose S$0.015 or 2.8 per cent to end at S$0.55, prior to the release of its business update for the quarter. Far East Orchard : O10 (FEOR): The hotel operator and property developer, along with its subsidiaries, are selling Rendezvous Hotel Perth Central and its business for A$18.5 million (S$16.5 million). On Monday, FEOR said the disposal will enable the group to realise the value of the hotel, and in turn, improve capital allocation and optimise returns for the company’s shareholders. Shares of Far East Orchard closed flat at S$1.02, before the news.Singapore Airlines : C6L (SIA): The national flag carrier has agreed to purchase 1,000 tonnes of sustainable aviation fuel from renewable fuel producer Neste. On Monday, SIA said this will make the group and its budget airline Scoot the first carriers to receive sustainable aviation fuel produced at Neste’s Singapore refinery. The counter ended Monday at S$6.55, up S$0.03 or 0.5 per cent, prior to the announcement.Cordlife Group : P8A: The cord-blood bank’s directors have offered different views on who will oversee the company’s ongoing developments in Singapore. This was in response to queries from the Singapore Exchange (SGX) ahead of the company’s May 14 annual general meeting. Shares of Cordlife ended Monday flat at S$0.12, before the latest bourse filing was released. SG Local NewsSIA and Scoot First Airlines to Get Neste's SingaporE-made Sustainable Fuel at Changi AirportThe Singapore Airlines (SIA) Group has signed an agreement with refinery Neste to purchase 1,000 tonnes of neat Neste MY Sustainable Aviation Fuel for airlines SIA and Scoot. This will make the two airlines the first operating out of Changi Airport to receive sustainable aviation fuel (SAF) produced by Neste in Singapore, said SIA, Scoot and Neste in a joint media release on Monday (May 6).Jefferies Asks Judge to Remove Managers of Weiss Multi-StrategyMANAGERS of Weiss Multi-Strategy Advisers are trying to use the company’s bankruptcy case to enrich themselves and should be replaced by a court-approved trustee, Jefferies Financial Group said in a court filing.The move comes days after Weiss filed for court protection and sued Jefferies in US bankruptcy court in Manhattan. The defunct hedge fund is seeking to recover US$20 million, alleging the money either wrongly went to Jefferies over other creditors or was obtained under the threat of litigation. Jefferies has denied the allegations and said Weiss is acting in bad faith.Possible Class Action Lawsuit against Cordlife by Customers Could Take at Least 2 YearsA REPRESENTATIVE action suit against beleaguered cord-blood bank Cordlife could take at least two years to conclude, should affected Cordlife customers decide to go through with such a lawsuit, said partners at law firm Withers KhattarWong.However, the law firm stressed that the case is at an early fact-gathering and consolidation stage, and that it is not recommending that customers take up such a representative action – also known as a class action-type suit – at this juncture.This comes after Withers KhattarWong held a town hall meeting for affected Cordlife customers on Friday (May 3). The discussion covered the possible legal actions they could take, as well as the stages that are likely to take place in a class-action lawsuit.","news_type":1},"isVote":1,"tweetType":1,"viewCount":18,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304567189573672,"gmtCreate":1715391801861,"gmtModify":1715391803841,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/00728\">$CHINA TELECOM(00728)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/00728\">$CHINA TELECOM(00728)$</a>&nbsp;","text":"$CHINA TELECOM(00728)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304567189573672","isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304567468212488,"gmtCreate":1715391791829,"gmtModify":1715391795301,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/00728\">$CHINA TELECOM(00728)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/00728\">$CHINA TELECOM(00728)$</a>&nbsp;","text":"$CHINA TELECOM(00728)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304567468212488","isVote":1,"tweetType":1,"viewCount":73,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304503237988488,"gmtCreate":1715376197429,"gmtModify":1715376201251,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> <a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a> <a href=\"https://ttm.financial/S/BNTX\">$BioNTech SE(BNTX)$</a>&nbsp;","text":"$Tiger Brokers(TIGR)$ $BioNTech SE(BNTX)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304503237988488","isVote":1,"tweetType":1,"viewCount":84,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304502816981280,"gmtCreate":1715376008170,"gmtModify":1715394730521,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;","text":"$Tiger Brokers(TIGR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304502816981280","isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304497975070864,"gmtCreate":1715374823986,"gmtModify":1715378950032,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304497975070864","repostId":"2434844398","repostType":2,"repost":{"id":"2434844398","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1715338729,"share":"https://www.laohu8.com/m/news/2434844398?lang=&edition=full","pubTime":"2024-05-10 18:58","market":"us","language":"en","title":"Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability","url":"https://stock-news.laohu8.com/highlight/detail?id=2434844398","media":"Reuters","summary":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with $Sanofi(GCVRZ)$ for COVID-19 vaccines in exchange for a st","content":"<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Stock Rockets over 200% as It Signs COVID-19 License Deal with Sanofi, Removes Doubt About Business Viability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-05-10 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker&#39;s market value.</p><p>Novavax’s U.S.-listed shares soared over 202% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b48e5547ae5b5695bb762a993b997e33\" tg-width=\"780\" tg-height=\"633\"/></p><p>In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.</p><p>Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax&#39;s Matrix-M adjuvant.</p><p>Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.</p><p>Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.</p><p>&#34;We&#39;re excited by the prospect of combining Novavax&#39;s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)&#34;, Sanofi&#39;s head of vaccines R&amp;D, Jean-Francois Toussaint, said in a statement.</p><p>Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.</p><p>Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.</p><p>Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D&#39;Souza)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4588":"碎股","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4007":"制药","SNY":"赛诺菲安万特","BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","NVAX":"诺瓦瓦克斯医药","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SNYNF":"Sanofi"},"source_url":"https://finance.yahoo.com/news/1-frances-sanofi-covid-19-061951520.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2434844398","content_text":"(Reuters) - Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker's market value.Novavax’s U.S.-listed shares soared over 202% in premarket trading.In February last year, Novavax raised doubts about its business viability after missing out on the COVID-19 vaccine windfall due to manufacturing issues that delayed filing for regulatory approval. Its COVID shot got U.S. approval in July 2022, long after Pfizer and Moderna were in use.Novavax said it would co-commercialize its COVID-19 vaccine with French drugmaker Sanofi and develop new COVID-19-influenza combination vaccines using Novavax's Matrix-M adjuvant.Sanofi will pay Novavax $500 million upfront and up to $700 million in development, regulatory and launch milestones, the companies said. Novavax will also get double-digit percentage royalty payments on sales of its COVID-19 and flu-COVID-19 combination vaccines.Sanofi will take a 4.9% stake in the U.S. drugmaker for $70 million. That values Novavax at about $1.4 billion, nearly double its market capitalisation of about $628 million as of Thursday but a far cry from its peak of $20 billion in 2021.\"We're excited by the prospect of combining Novavax's adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines (...)\", Sanofi's head of vaccines R&D, Jean-Francois Toussaint, said in a statement.Novavax also reported that its net loss narrowed to $148 million in the first quarter from $294 million in the year-ago period.Its revenue rose to $94 million from $81 million and the company said it expects full-year revenue of $400 million to $600 million.Novavax also said plans to reduce 2025 research and development expenses to below $500 million, a portion of which it expects to recover from Sanofi under their deal. (Reporting by Tassilo Hummel; Reporting by Shubham Kalia and Utkarsh Shetti in Bangalore; Editing by Benoit Van Overstraeten and Savio D'Souza)","news_type":1},"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":304495767683312,"gmtCreate":1715374286171,"gmtModify":1715378943979,"author":{"id":"4178343809649462","authorId":"4178343809649462","name":"Yoon Yoon","avatar":"https://community-static.tradeup.com/news/6c309add317110bffcb99b249441675d","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"title":"Cheers to a great start!","htmlText":"Find out more here: <a href=\"https://www.tigerbrokers.com.sg/activity/forapp/welcome/sgp.html?adcode=AC1713167566154PhgMAh&amp;skin=1&amp;os=iOS&amp;account_id=20240509162636932&amp;is_invite=true&amp;utm_source=invite&amp;utm_campaign=AC1713171607756uKaqcQ&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=323ef2663e1378c2f4d76642b6e1f817&amp;invite=OOMW2C&amp;lang=en_US\">Cheers to a great start!</a> Receive rewards up to USD 3600*","listText":"Find out more here: <a href=\"https://www.tigerbrokers.com.sg/activity/forapp/welcome/sgp.html?adcode=AC1713167566154PhgMAh&amp;skin=1&amp;os=iOS&amp;account_id=20240509162636932&amp;is_invite=true&amp;utm_source=invite&amp;utm_campaign=AC1713171607756uKaqcQ&amp;utm_medium=tiger_community&amp;platform=iOS&amp;shareID=323ef2663e1378c2f4d76642b6e1f817&amp;invite=OOMW2C&amp;lang=en_US\">Cheers to a great start!</a> Receive rewards up to USD 3600*","text":"Find out more here: Cheers to a great start! Receive rewards up to USD 3600*","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/304495767683312","isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}